| Stereochemistry | RACEMIC |
| Molecular Formula | C13H19NO2 |
| Molecular Weight | 221.2955 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CC(O[C@H]2CCNC[C@H]2O)=C1C
InChI
InChIKey=ZHFIAFNZGWCLHU-YPMHNXCESA-N
InChI=1S/C13H19NO2/c1-9-4-3-5-12(10(9)2)16-13-6-7-14-8-11(13)15/h3-5,11,13-15H,6-8H2,1-2H3/t11-,13+/m1/s1
| Molecular Formula | C13H19NO2 |
| Molecular Weight | 221.2955 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Ifoxetine was developed as an unusual drug that specifically and selectively blocks the 5-HT reuptake in the brain without affecting the 5-HT uptake processes in the periphery (blood platelets). The drug was undergoing phase II clinical trials for the treatment of depression; however, the study was suspended.
